Lyka Labs share news, announcements and annual reports
NSE: LYKALABSBSE: 500259Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 2 Nov 2026. Previous close ₹76.60.
2 Nov: open ₹76.00, high ₹76.00, low ₹75.07
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹271 Cr2,310th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.83
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −4.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −3.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.47
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 15,895
Lyka Labs share news and announcements
1,493 announcements, routine notices left out, newest first. Page 27 of 30.
Dec 2011
30 Dec · Business
Updates - Agreement for Transfer of Know How/ Technology30 Dec · Updates
Company has recently entered into a Technology Transfer Agreement with a Pharma Company based in Republic of Turkey for a lyophilized formulation, for a consideration of US $ 2,50,000 and Royalty for five years.
Nov 2011
25 Nov · Updates
Company has entered into a "Technical Assistance Agreement" for "Lyophilized Formulations" with a Company based at Indonesia.25 Nov · Business
Technical Assistance Agreement18 Nov · With reference to the earlier announcement dated December 17, 2011, Lyka Labs Ltd has now informed BSE that in the said announcement the Company have mentioned MOU entered with "European ....
Updates to MOU for Transfer of Technical Know How / Technology17 Nov · Lyka Labs Ltd has informed BSE that the Company has entered MOU with European based Company for Transfer Known- How / Technology to manufacture lyophilized product for a consideration of ....
MOU for Transfer of Technical Know How / Technology16 Nov · Lyka Labs Ltd has informed BSE that Shri. S S Upadhyaya - Director of the Company expired on November 08, 2011.
Demise of Director16 Nov · Demise of Director
Shri. S. S. Upadhyaya - Director of the Company expired on November 08, 2011.15 Nov · Management
Shri. Manish Jayavant - Chief Finance Officer of the Company has resigned w.e.f. October 22, 2011.15 Nov · Lyka Labs Ltd has informed BSE that Shri. Manish Jayavant - Chief Finance Officer of the Company has resigned w.e.f. October 22, 2011.
Resignation of CFO15 Nov · Results
4 Nov · Updates
Company has been conferred Certificate of Appreciation Patent Award for the year 2010-2011 by Pharmaceuticals Export Promotion Council in recognition of commendable contribution to R&D in formulation sector.4 Nov · Business
Patent Award2 Nov · Updates
Company has received permission from Drugs Controller General (India) vide their letter dated September 14, 2011 to manufacture Glutathione for Injection. Glutathione Injection is used for the treatment of Alcoholic Liver Diseases such as: (1) Alcoholic Fatty Liver (2) Fibrosis (3) Cirrhosis (4) Hepatitis . Lyka is the first Company in India to get the permission of Glutathione Injection.2 Nov · Lyka Labs Ltd has informed BSE that the Company has received permission from Drugs Controller General (India) vide their letter dated September 14, 2011 to manufacture Glutathione for Injection. ....
DCGI approval Glutathione Injection2 Nov · Board meeting
To consider and take on record the Un-audited Financial Results and also Consolidated Financial Results of the Company for the quarter September 30, 2011.
Oct 2011
11 Oct · Lyka Labs Ltd has informed BSE that the Company has extended its Financial Year ending on September 30, 2011 to March 31, 2012 which has been approved by the Registrar of Companies, Gujarat ....
Extension of Financial Year5 Oct · Extension of Financial Year
Company has extended its Financial Year ending on September 30, 2011 to March 31, 2012 which has been approved by the Registrar of Companies, Gujarat vide their letter dated September 30, 2011. In view of this the accounts for the current Financial Year will be prepared for a period of 18months i.e. October 01, 2010 to March 31, 2012.
Aug 2011
18 Aug · Management
Change in Directorship18 Aug · Management
Term of Directorship of Mr. V.S.Taksali - Executive Director ended on July 31, 2011 and he has tendered his resignation as Director from August 01, 2011. The Board has considered his resignation in their meeting held on August 12, 2011.2 Aug · Board meeting
To consider and take on record the Unaudited Financial Results of the Company for the quarter ended June 30, 2011.
Jul 2011
19 Jul · Lyka Labs Ltd has informed BSE that as per the Order passed by High Court of Gujarat at Ahmedabad, the Company's Plant at Ankleshwar has been de-sealed. with effect from July 18, 2011.
De-seal of Factory at Ankleshwar19 Jul · Updates
As per the Order passed by High Court of Gujarat at Ahmedabad, the Company's Plant at Ankleshwar has been de-sealed with effect from July 18, 2011.4 Jul · Updates
Vide its letter dated July 04, 2011 that: "Our factory at Ankleshwar is sealed, without following due procedure of law, by the Mamlatdar of Ankleshwar for alleged recovery of dues towards DPEA, under DPCO 1979. This has happened despite the matter being Sub Judice before the Hon'ble Gujarat High Court. The hearing is on in the matter in the Hon'ble Gujarat High Court and we hope the matter will be resolved soon".4 Jul · Lyka Labs Ltd has informed BSE that Company's factory at Ankleshwar is sealed, without following due procedure of law, by the Mamlatdar of Ankleshwar for alleged recovery of dues towards ....
Closure of Factory at Ankleshwar
Jun 2011
May 2011